原文链接：https://hello-pharma.com/category/pharma-serialization/

下文为相关翻译。

Pharma Serialization药品序列化

Pharma serialization is the foundation of modern pharmaceutical supply chain security. Every prescription pack manufactured today carries a unique digital identity that can be tracked, verified, and traced from the packaging line to the patient. Behind that simple idea sits one of the largest regulatory, technological, and operational transformations the pharmaceutical industry has ever undertaken.

药品序列化是现代制药供应链安全的基础。如今制造的每套处方药包都带有独特的数字身份，可以从包装线追踪、验证并追踪到患者本人。在这个简单的想法背后，是制药行业有史以来最大规模的监管、技术和运营转型之一。

By May 2026, more than 78 countries enforce some form of pharma serialization, the US DSCSA has reached full enforcement, the EU FMD has been operating at scale for seven years across 30 EEA markets, and India, Russia, China, Brazil, Turkey, Saudi Arabia, the UAE, and South Korea all operate mature national systems. The global pharma track-and-trace software market is estimated at USD 2.5 billion in 2026 and projected to reach USD 9.7 billion by 2035, growing at a 16.1 percent compound annual growth rate. Approximately 65 percent of pharmaceutical packaging lines globally now operate with serialization modules.

截至2026年5月，已有超过78个国家执行某种形式的药品序列化，美国DSCSA已全面执行，欧盟防伪指令已在30个欧洲经济区市场大规模运行七年，印度、俄罗斯、中国、巴西、土耳其、沙特阿拉伯、阿联酋和韩国均运行成熟的国家系统。全球制药追踪软件市场2026年估计规模为25亿美元，预计到2035年将达到97亿美元，年复合增长率为16.1%。全球约65%的药品包装线现已使用序列化模块。

For any manufacturer, CDMO, wholesaler, dispenser, or Marketing Authorisation Holder operating in this environment, pharma serialization is no longer a project. It is permanent operational infrastructure that touches every part of the business, from packaging line engineering to global trade, from quality assurance to patient safety, from supply chain analytics to brand protection.

对于任何在该环境中运营的制造商、CDMO、批发商、配药商或上市许可持有人来说，药品序列化不再是一个项目。它是贯穿业务方方面面的永久运营基础设施，从包装线工程到全球贸易，从质量保证到患者安全，从供应链分析到品牌保护。

This pillar guide brings together everything pharmaceutical companies need to understand about serialization in 2026. It explains what serialization is, why it matters, the global regulatory landscape, the underlying technology stack, the complementary frameworks (track and trace, aggregation, UDI for combination products), the major regional mandates (DSCSA, EU FMD, India CDSCO and DGFT iVEDA), and how to choose the right software and vendors. Each section links to a detailed deep-dive article for readers who want to go deeper.

本支柱指南汇集了制药公司在2026年关于序列化需要了解的所有内容。它解释了序列化是什么、其重要性、全球监管环境、底层技术栈、互补框架（追踪与追踪、聚合、组合产品的统一独立数据排放）、主要区域要求（DSCSA、EU FMD、印度CDSCO和DGFT iVEDA），以及如何选择合适的软件和供应商。每个部分都链接到一篇详细的深入文章，供想要深入了解的读者使用。

What Is Pharma Serialization?什么是药品序列化？

Pharma serialization is the practice of assigning a unique, machine-readable identifier to every saleable unit of pharmaceutical product, recording its movement through the supply chain, and exchanging that data with regulators, trade partners, and verification systems.

药品序列化是指为每一个可销售的药品单位分配一个唯一且机器可读的标识符，记录其在供应链中的流动，并将这些数据与监管机构、贸易伙伴和验证系统交换。

A serialized pack typically carries a 2D DataMatrix barcode (or a QR code in some markets like India) containing four mandatory data elements built on GS1 standards: the Product Code (GTIN or NTIN), a randomized serial number, the batch or lot number, and the expiry date. These same data elements appear in human-readable form on the pack so they can be inspected without scanning.

序列化包装通常带有一个二维DataMatrix条形码（某些市场如印度为二维码），包含四个基于GS1标准的必备数据元素：产品代码（GTIN或NTIN）、随机序列号、批号或批号以及有效期。这些数据元素以人类可读的形式出现在数据包上，便于无需扫描即可检查。

Behind the barcode sits a complete technology infrastructure that generates serial numbers, prints them on packs, verifies print quality, links packs into hierarchical packaging units, transmits data to trading partners using the EPCIS standard, and reports to national repositories and verification systems. Together, these capabilities deliver three interconnected outcomes that serve patients, regulators, and businesses simultaneously: authentication, traceability, and intelligence.

条码背后是完整的技术基础设施，能够生成序列号、在包装上打印、验证印刷质量、将包装连接到分层包装单元、使用EPCIS标准向贸易伙伴传输数据，并向国家仓库和验证系统报告。这些能力共同带来了三项相互关联的结果，同时服务于患者、监管机构和企业：身份验证、可追溯性和情报。

For a deeper introduction to the full architecture of pharma serialization solutions, see the dedicated guide on pharma serialization solutions.

如需深入了解药品序列化解决方案的完整架构，请参阅专门的药品序列化解决方案指南。

Why Pharma Serialization Matters in 2026为什么药品序列化在2026年很重要

The strategic case for pharma serialization rests on six interconnected drivers.

药品序列化的战略理由基于六个相互关联的驱动因素。

Patient safety. The World Health Organization estimates that 1 in 10 medical products in low- and middle-income countries is falsified or substandard. Serialization is the most effective defense against counterfeit, stolen, and diverted medicines entering the legitimate supply chain.

患者安全。世界卫生组织估计，低收入和中等收入国家每十个医疗产品中就有1个是伪造或不达标的。序列化是防止假冒、被盗和被转移药品进入合法供应链的最有效防御。

Regulatory survival. With DSCSA enforced in the US, EU FMD mature across Europe, and 78 plus other markets mandating unique pack identifiers, no pharmaceutical company can sell across multiple markets without robust serialization infrastructure.

监管生存的需要：随着美国执行DSCSA，欧盟FMD在欧洲成熟落地，且有78个以上市场强制要求唯一包装标识符，任何制药公司若没有完善的序列化基础设施，就无法开展多市场药品销售业务。

Faster, more precise recalls. Granular pack-level traceability enables companies to recall only affected serial numbers rather than entire batches, saving cost and protecting overall supply.

更快、更精准的召回：精细化包装级追溯，使企业仅召回受影响的序列号单元，无需召回整批货物，节约成本并保障整体药品供应。

Anti-diversion and anti-counterfeit defense. Real-time serialization data exposes when stolen or diverted packs reappear in legitimate supply chains, and verified packaging hierarchies make counterfeit insertion extremely difficult.

防窜货与防伪能力：实时序列化数据可识别被盗或窜货的药品包装重新流入合法供应链的情况；经过核验的包装层级聚合关系，极大提升假药介入供应链的难度。

Operational efficiency. Distribution centers report 50 to 80 percent reductions in receiving time after proper aggregation is implemented. The pharmaceutical industry loses an average of 4.5 percent of potential revenue annually to supply chain inefficiencies, and serialization data directly addresses many of those losses.

运营效率提升：配送中心在落地规范的包装聚合方案后，收货作业时长可降低50%‑80%。制药行业每年因供应链低效平均损失4.5%的潜在收入，而序列化数据可直接缓解其中大量损失。

Foundation for digital transformation. The EU’s emerging Digital Product Passport framework under the Ecodesign for Sustainable Products Regulation will extend serialization into sustainability and ingredient origin data. Companies with strong serialization infrastructure today are best positioned for the next decade of pharmaceutical regulation and supply chain intelligence.

数字化转型的基础：欧盟依据《可持续产品生态设计法规》正在推出的数字产品护照（DPP）框架，会将序列化能力延伸至可持续发展以及原料溯源数据领域。当下已具备完善序列化基础设施的企业，将在未来十年的药监合规与供应链智能化建设中占据优势地位。

The Global Pharma Serialization Landscape in 2026  2026 年全球制药行业序列化格局

Pharma serialization is enforced in fundamentally different ways across the major markets. Understanding which framework applies to your products is the starting point for any compliance strategy.

各主要市场对制药序列化的强制实施模式存在本质差异。厘清自身产品适用哪一套法规体系，是制定所有合规策略的起点。

For multi-market pharmaceutical companies, the most efficient approach is a single multi-market serialization platform that handles every regulatory regime from a unified codebase rather than running parallel systems for each country.

对于布局多国市场的制药企业，最高效的方案是搭建一套多市场一体化序列化平台：基于统一代码底座，适配所有国家法规体系，而不是为每个国家独立部署多套并行系统。

The Two US-Specific Frameworks: DSCSA and UDI美国两套独立体系：DSCSA 与 UDI

The United States operates two parallel pharmaceutical identification regimes, and combination product manufacturers must understand the difference.

美国并行运行两套药品标识监管体系，药械组合产品生产商必须厘清二者差异。

DSCSA: The Drug-Side Framework DSCSA：药品端监管框架

The Drug Supply Chain Security Act, signed into law in 2013, governs prescription drug serialization and traceability in the US. Full enforcement is now active across all trading partner categories.

《药品供应链安全法案》（DSCSA）于 2013 年正式立法，管控美国境内处方药序列化与产品追溯。目前该法案已对全部类别贸易伙伴全面强制执行。

DSCSA requires every prescription drug pack to carry a unique product identifier (NDC plus serial number, batch, expiry), transaction data exchange via EPCIS, verification of suspect product through a Verification Router Service, Authorized Trading Partner credentialing, suspect and illegitimate product handling, and 6-year recordkeeping. In late 2024, the FDA issued a 23 million dollar fine to a major distributor for serialization failures, signaling that enforcement is real and aggressive.

DSCSA 要求：每一个处方药包装必须带有唯一产品标识符（NDC 码 + 序列号、批次、有效期）；通过 EPCIS 完成交易数据交换；借助验证路由服务（VRS）开展可疑产品核验；开展授权贸易伙伴资质认证；可疑及非法药品处置；以及保存 6 年记录。2024 年末，FDA 因序列化不合规问题对一家大型分销商处以 2300 万美元罚款，表明监管执法已落地且力度强劲。

For a complete walkthrough of DSCSA enforcement, requirements, and how to choose a compliant platform, see the detailed guide on DSCSA compliance solutions.

如需完整解读 DSCSA 执法规则、合规要求以及如何选择合规平台，请参阅 DSCSA 合规解决方案详细指南。

UDI: The Device-Side Framework UDI：医疗器械端监管框架

The Unique Device Identifier system applies to medical devices and to the device constituent parts of combination products such as autoinjectors, prefilled syringes, inhalers, on-body injectors, and transdermal delivery systems. UDIs are issued through FDA-accredited agencies (GS1, HIBCC, ICCBBA), applied to device labeling, and submitted to the Global Unique Device Identification Database (GUDID).

医疗器械唯一标识（UDI）体系适用于医疗器械，以及药械组合产品中的器械组分，例如自动注射器、预充针筒、吸入器、穿戴式注射器与经皮给药系统。UDI 码由 FDA 认可的发证机构（GS1、HIBCC、ICCBBA）分配，印制在器械标签上，并上报至全球医疗器械唯一标识数据库（GUDID）。

The FDA’s June 2025 draft guidance “Unique Device Identifier (UDI) Requirements for Combination Products” clarified that UDI requirements apply to device constituents on top of, not instead of, drug-side DSCSA serialization obligations. A prefilled syringe combination product needs DSCSA serialization on the drug-side packaging, UDI labeling on the device component, GUDID submission for the device, and in many cases EU FMD compliance for the European market.

FDA 在 2025 年 6 月发布的《药械组合产品医疗器械唯一标识（UDI）要求》草案指南中明确：UDI 要求针对器械组分执行，是在药品端 DSCSA 序列化义务之外额外增加的要求，而非替代 DSCSA。预充针药械组合产品，需要在药品包装上满足 DSCSA 序列化要求；器械组分施加 UDI 标签；器械信息上报 GUDID；如面向欧洲市场，多数情况下还需符合欧盟 FMD（药品防伪指令）合规要求。

For a complete walkthrough of UDI requirements for combination products and how they intersect with DSCSA, see the detailed guide on unique device identifier (UDI) pharma.

如需完整解读药械组合产品 UDI 要求，以及 UDI 与 DSCSA 之间的交叉合规规则，请查阅医药行业医疗器械唯一标识（UDI）详细指南。

The European Framework: EU FMD欧盟监管框架：欧盟药品防伪指令（EU FMD）

The European Union’s Falsified Medicines Directive (2011/62/EU) and its Delegated Regulation (2016/161) have governed prescription medicine serialization across all 30 EEA countries since February 9, 2019. By 2026, the European Medicines Verification System celebrated seven years of continuous operation, connecting more than 2,900 Marketing Authorisation Holders, 4,000 wholesale distributors, 115,000 commercial pharmacies, and 6,000 hospital pharmacies.

欧盟《假药指令》（2011/62/EU）及其授权法规（2016/161）自 2019 年 2 月 9 日起，在全部 30 个欧洲经济区（EEA）国家管控处方药序列化。至 2026 年，欧洲药品验证系统（EMVS）已稳定运行 7 年，接入超过 2900 家上市许可持有人、4000 家药品批发分销商、115000 家社会药房以及 6000 家医院药房。

EU FMD has three core requirements. A unique identifier (Product Code, serial number, batch, expiry) encoded in a 2D DataMatrix code on every prescription pack. A tamper-evident device on the packaging that allows recipients to verify the pack has not been opened. Upload of pack data to the EU Hub before market release, with point-of-dispense verification at pharmacies and hospitals via the relevant National Medicines Verification System.

欧盟 FMD 包含三项核心要求：1. 在每一处处方药包装上，将唯一标识符（产品代码、序列号、批次、有效期）编入二维 DataMatrix 码；2. 包装配备防拆装置，供接收方核验包装未曾开启；3. 产品上市前将包装数据上传至欧盟中央数据库（EU Hub）；药房与医院在药品调配环节，通过对应国家药品验证系统进行药品核验。

The European Commission’s 2024 evaluation report confirmed only 30 cases of falsified medicines in the legal supply chain between 2011 and 2024, with just 11 confirmed cases since 2019, demonstrating that the framework has been effective at protecting patients. Brexit changed the landscape for the United Kingdom: medicines authorized solely for Great Britain (PLGB) no longer require FMD safety features, while Northern Ireland continues to follow EU rules under the Windsor Framework.

欧盟委员会 2024 年评估报告证实：2011–2024 年间，合法供应链内仅发现 30 起假药案例；2019 年法规落地后仅 11 起，证明该监管体系可有效保护患者安全。脱欧改变了英国的合规格局：仅获批在大不列颠地区上市（PLGB）的药品不再强制要求 FMD 安全特征；北爱尔兰则依据《温莎框架》继续遵循欧盟 FMD 规则。

For a complete walkthrough of EU FMD requirements, EMVS architecture, parallel trade obligations, and operational best practices, see the detailed guide on EU FMD serialization requirements. 如需完整解读欧盟 FMD 要求、EMVS 架构、平行贸易相关义务以及实操最佳实践，请查阅欧盟 FMD 序列化要求详细指南。

The Indian Framework: CDSCO, DGFT iVEDA, and API QR Codes

印度监管框架：CDSCO、DGFT iVEDA 与原料药二维码

India operates one of the world’s most layered pharma serialization frameworks, with separate regulations for upstream APIs, domestic finished products, and exports.

印度拥有全球层级最复杂的药品序列化监管体系之一，针对上游原料药、国内上市制剂以及出口药品分别制定监管规则。

Pillar 1: API QR Code Labeling. Effective January 1, 2023, all imported and domestically manufactured Active Pharmaceutical Ingredients must carry QR codes on each level of packaging.

支柱 1：原料药二维码标签。自 2023 年 1 月 1 日起，所有进口及本土生产的原料药，在每一级包装上均必须粘贴二维码。

Pillar 2: Top 300 Brands Mandate. Under amended Rule 96 of the Drugs Rules 1945 (Notification G.S.R. 823(E) dated November 17, 2022), the 300 highest-selling drug formulations listed in Schedule H2 must carry QR codes on primary or secondary packaging. The rule came into effect on August 1, 2023. In August 2025, the government confirmed that DTAB has approved gradual expansion of the QR code requirement to all vaccines, antimicrobials, narcotics, and psychotropic substances.

支柱 2：销量前 300 品牌强制赋码。依据修订后的《1945 年药品法规》第 96 条（2022 年 11 月 17 日发布 G.S.R. 823 (E) 公告），列入 H2 附表的销量排名前 300 药品制剂，必须在一级或二级包装上加贴二维码。该法规于 2023 年 8 月 1 日生效。印度政府于 2025 年 8 月确认，药品技术咨询委员会（DTAB）已批准逐步将二维码要求扩展至全部疫苗、抗菌药、麻醉药品及精神药品。

Pillar 3: DGFT iVEDA Export Reporting. All pharmaceutical exports from India require barcoding at primary, secondary, and tertiary packaging levels, with serialization and aggregation data reported to the iVEDA portal. Indian customs has held shipments at the border when iVEDA authentication failed.

支柱 3：DGFT iVEDA 出口申报。所有印度出口药品，其一级、二级、三级包装均需赋条码；序列化与包装层级关联数据（聚合数据）需上报 iVEDA 平台。如 iVEDA 核验失败，印度海关可在口岸扣留货物。

India is the world’s third largest pharmaceutical industry by volume, accounts for approximately 60 percent of global vaccine production, and supplies generics to more than 200 countries. CDSCO officials tested 96,713 drug samples in the 2022 to 2023 financial year and identified 3,053 as substandard and 424 as spurious or adulterated, underscoring why the framework matters.

按产量计算，印度是全球第三大医药生产国，承担全球约 60% 疫苗产能，向 200 多个国家供应仿制药。CDSCO 在 2022–2023 财年抽检 96713 份药品样品，检出 3053 份不合规样品、424 份假药或掺假药品，凸显该套监管体系的必要性。

For a complete walkthrough of India’s three-pillar framework, GS1 implementation, iVEDA reporting, and global alignment strategies for Indian exporters, see the detailed guide on India pharma barcoding requirements.

如需完整解读印度三大支柱监管框架、GS1 落地实施、iVEDA 申报，以及印度出口企业的全球合规协同策略，请查阅印度药品条码要求详细指南。

The Five-Layer Architecture of Pharma Serialization Systems

药品序列化系统的五层架构

Pharma serialization implementations follow a standardized layered architecture defined by ISA-95 and adapted for pharma. Most modern platforms operate across multiple layers of this stack.

药品序列化项目实施遵循 ISA-95 定义的标准化分层架构，并针对制药行业进行适配。当前主流合规平台均在该技术栈的多个层级上运行。

A complete serialization deployment requires either a single vendor that covers all five levels or a combination of vendors with validated integration points. The choice between cloud-native multi-tenant SaaS, on-premises enterprise software, and hybrid models depends on existing IT landscape, manufacturing footprint, data sovereignty requirements, and total cost of ownership considerations.

For a complete walkthrough of architecture, features, deployment models, and selection criteria for serialization software, see the detailed guide on serialization software pharma.

一套完整的序列化实施项目，可选择一家覆盖全部五层架构的供应商，也可选择多家供应商组合，但必须对各接口集成点完成验证。在云原生多租户 SaaS、本地部署企业软件以及混合部署模式之间做选型，取决于企业现有 IT 架构、生产布局、数据主权要求以及总拥有成本考量。如需完整讲解序列化软件的架构、功能、部署模式以及选型标准，请参阅制药行业序列化软件详细指南。

Track and Trace: From Serial Numbers to Supply Chain Visibility

Serialization gives every pack a unique identity. Track and trace is the system that records and exchanges what happens to those serialized packs across the supply chain. The two are complementary and interdependent.

序列化赋予每个药品包装唯一身份标识。追溯系统负责记录并传递这些赋码包装在整个供应链中的流转信息。二者互为补充、相互依存。

Track and trace adds two critical capabilities on top of serialization. The ability to know in real time where a specific pack is currently located. The ability to look backward and reconstruct where it has been, who handled it, and when. To deliver these, track and trace systems rely on three technologies working together: serialization (unique pack-level identifiers), aggregation (parent-child packaging hierarchies), and event capture and exchange using the EPCIS standard.

追溯在序列化基础上新增两项核心能力：实时定位单个包装当前所处位置；回溯重建该包装的流转路径、经手方与时间节点。为实现上述能力，追溯系统依靠三项技术协同工作：序列化（包装级唯一标识）、聚合（包装父子层级关系）、基于 EPCIS 标准的事件采集与数据交换。

EPCIS (Electronic Product Code Information Services), maintained by GS1, is the universal language of pharmaceutical track and trace. It defines the data model (what, when, where, why), the vocabulary (commissioning, packing, shipping, receiving, decommissioning), and the interfaces for exchanging supply chain event data. EPCIS 1.2 is the most widely deployed version today, with EPCIS 2.0 (JSON-based, REST API-native) emerging as the new standard for cloud-first pharmaceutical networks.

EPCIS（电子产品代码信息服务）由 GS1 负责维护，是药品追溯领域的通用标准语言。它定义了数据模型（何事、何时、何地、为何）、业务术语（激活赋码、装箱、发货、收货、注销）以及供应链事件数据交换接口。目前 EPCIS 1.2 为应用最广的版本；基于 JSON、原生支持 REST API 的 EPCIS 2.0，正逐步成为面向云优先医药网络的新标准。

For a complete walkthrough of how track and trace works, EPCIS standards, common pain points, and how to build a future-ready strategy, see the detailed guide on track and trace pharma.

如需完整解读追溯原理、EPCIS 标准、常见痛点以及如何构建面向未来的追溯策略，请查阅医药行业产品追溯详细指南。

Aggregation: Where Serialization Becomes Operationally Powerful

聚合关系：让序列化发挥业务效能的核心手段

Aggregation is the process of creating verified parent-child relationships between serialized packaging units (unit, bundle, case, pallet). Without aggregation, verifying the contents of a sealed case in a distribution center would mean opening it, scanning every carton, and rebuilding the shipment from scratch.

聚合关系，是在已赋序列化码的包装单元（销售单元、捆包、纸箱、托盘）之间建立经验证的父子关联关系。若无聚合能力，在配送中心核验密封纸箱内货品时，只能开箱、逐盒扫码，重新完成整批货物的信息重建。

A typical pharma packaging hierarchy uses GS1 identifiers across multiple levels. The unit (saleable carton, bottle, or blister pack) carries an SGTIN (Serialized Global Trade Item Number). Bundles, cases, and pallets carry SSCC (Serial Shipping Container Code) identifiers. Each level is digitally linked to the units it contains, so scanning the outer container reveals every serial number inside without opening the package.

典型制药包装层级在各级包装上采用 GS1 标识：销售单元（可销售纸盒、药瓶、泡罩板）使用 SGTIN（序列化全球贸易项目代码）；捆包、纸箱与托盘使用 SSCC（系列货运包装箱代码）。各层级与内含单元建立数字关联，因此扫描外层包装，即可获取内部所有序列号，无需开箱。

Aggregation is legally mandatory in Russia, Brazil, Turkey, Saudi Arabia, the UAE, South Korea, China, Argentina, and India (for exports). It is not explicitly required under US DSCSA or EU FMD, but it is commercially expected by most large wholesalers in both regions because it enables faster receiving, more targeted recalls, anti-diversion defense, and inference-based supply chain logistics. For any multi-market manufacturer, aggregation is now effectively a global default.

俄罗斯、巴西、土耳其、沙特阿拉伯、阿联酋、韩国、中国、阿根廷以及印度（出口药品）强制要求包装聚合。美国 DSCSA 与欧盟 FMD 法规虽未明文强制聚合，但两地大型批发商普遍将其作为商业要求：聚合可加快收货核验、实现精准召回、防范药品串货，并支撑基于信息推演的供应链物流管理。对于面向多国市场的制药厂商而言，包装聚合事实上已经成为全球通用标配。

Aggregation systems combine vision cameras, barcode scanners, robotic case packers and palletizers, print-and-apply SSCC labeling units, tunnel scanners, and reject mechanisms with sophisticated software for parent-child relationship management, exception handling, and EPCIS Aggregation Event generation. Implementation can be manual, semi-automatic, or fully automatic depending on line volumes and capital budget.

聚合系统集成视觉相机、条码扫描器、机器人装箱机与码垛机、SSCC 打印贴标单元、通道式扫描设备、剔除机构，并配套专业软件，用于父子码关系管理、异常处理以及生成 EPCIS 聚合事件。根据产线产能与资本预算，可采用人工、半自动或全自动实施方案。

For a complete walkthrough of aggregation systems, hardware, software, regulatory status, EPCIS Aggregation Events, and common implementation pitfalls, see the detailed guide on aggregation systems for pharma packaging.

如需完整解读聚合系统、软硬件组成、各国法规要求、EPCIS 聚合事件以及项目落地常见坑点，请查阅制药包装聚合系统详细指南。

Choosing the Right Pharma Serialization Vendor制药序列化供应商选型

The serialization vendor market in 2026 organizes broadly into five categories. Enterprise multi-tenant cloud networks (TraceLink Opus is the dominant example, with 290,000+ network members). Enterprise on-premises and hybrid platforms (SAP ATTP leads here). Pure-play serialization specialists (Systech UniTrace, OPTEL VerifyBrand, Antares Vision and rfxcel, Movilitas, SEA Vision, Arvato CSDB, Covectra AuthentiTrack). Mid-market and SME-focused platforms (tracekey mytracekey PHARMA, SoftGroup SATT, LSPedia, Vimachem, Adents). Dispenser and wholesale-focused tools (InfiniTrak, TrackTraceRX, LSPedia OneScan).

2026 年序列化供应商市场大致分为五类：

Ø  企业级多租户云网络平台（代表产品 TraceLink Opus，拥有超过 290000 家网络成员）；

Ø  企业本地部署与混合架构平台（SAP ATTP 为行业标杆）；

Ø  专注序列化领域的专业厂商（Systech UniTrace、OPTEL VerifyBrand、Antares Vision+rfxcel、Movilitas、SEA Vision、Arvato CSDB、Covectra AuthentiTrack）；

Ø  面向中端市场与中小企业 SME 的平台（tracekey mytracekey PHARMA、SoftGroup SATT、LSPedia、Vimachem、Adents）；

Ø  面向调配机构与批发分销商的专用工具（InfiniTrak、TrackTraceRX、LSPedia OneScan）。

The right vendor depends on company profile, market footprint, packaging line hardware, ERP landscape, and growth trajectory. Independent benchmarks have produced specific guidance for common profiles. Innovator pharma often selects a TraceLink plus Systech combination despite an 18 percent cost premium for reliability. Generic manufacturers typically favor Antares Vision plus rfxcel for handling frequent product changes. Distributors often choose rfxcel for fastest ROI at approximately 9 months. Small dispensers gravitate toward InfiniTrak, TrackTraceRX, or LSPedia OneScan for cost-effective DSCSA compliance.

合适供应商的选择取决于企业类型、市场覆盖范围、包装产线硬件、ERP 系统环境以及业务增长规划。第三方基准报告针对不同企业类型给出选型参考： 创新药企业通常选用 TraceLink 搭配 Systech 的组合方案，尽管成本高出 18%，但胜在稳定性； 仿制药企业一般倾向 Antares Vision+rfxcel 方案，能够应对频繁的产品变更； 分销商大多选择 rfxcel，投资回报周期最短，约 9 个月； 小型调配机构倾向 InfiniTrak、TrackTraceRX 或 LSPedia OneScan，以较低成本实现 DSCSA 合规。

Hidden costs to watch for include proprietary hardware lock-in (some platforms require specific cameras at approximately 28,000 USD per line), mandatory infrastructure dependencies, change control complexity (master data updates that can take 14 to 22 weeks in some platforms), FDA Form 483 remediation budgets (75,000 to 150,000 USD typical), validation services (15 to 40 percent of initial implementation cost), trading partner onboarding fees, and premium support tiers. Always demand a fully-loaded 5-year total cost of ownership model from every shortlisted vendor.

需要重点留意隐性成本：专有硬件绑定（部分平台要求配套指定相机，单条产线约 28000 美元）、强制依赖特定基础设施、变更控制复杂度高（部分平台主数据更新周期长达 14–22 周）；FDA 483 缺陷项整改预算（通常 75000–150000 美元）；验证服务费用（占初始实施成本 15%~40%）；贸易伙伴接入费以及高级技术支持套餐费用。务必要求每一家入围供应商提供完整包含所有项目的 5 年总拥有成本 TCO 测算模型。

For a complete vendor-by-vendor comparison covering features, pricing, deployment models, best-fit profiles, and selection methodology, see the detailed guide on serialization vendors comparison.

如需各供应商完整对比（功能、报价、部署模式、适配企业类型、选型方法），请查阅序列化供应商对比详细指南。

Building a Future-Ready Pharma Serialization Strategy构建面向未来的制药序列化战略

A complete pharma serialization strategy in 2026 should rest on ten principles, drawn from the experience of leading global manufacturers and CDMOs.

2026 年，一套完备的制药序列化战略应基于十大原则，这些原则源自全球头部制药企业与合同研发生产组织（CDMO）的实践经验。

1：Treat serialization as permanent operational infrastructure. Not as a one-time compliance project but as a core capability that will evolve for the next decade and beyond.

将序列化视为永久性运营基础设施。它不是一次性合规项目，而是未来十年乃至更长时间持续迭代的核心能力。

2：Start with master data governance. Clean, harmonized GTIN, NDC, GLN, batch, expiry, and product hierarchy data is the foundation. Master data inconsistencies sink more projects than any other factor.

从主数据治理着手。准确、统一的 GTIN、NDC、GLN、批次、有效期及产品层级数据是基础。相比其他因素，主数据不一致是导致项目失败的首要原因。

3：Choose a multi-market platform. Single-platform support for DSCSA, EU FMD, India CDSCO and DGFT iVEDA, Russia CRPT, UAE Tatmeen, Saudi RSD, Brazil ANVISA, Turkey ITS, and other regimes dramatically reduces complexity and cost compared to running parallel systems.

选用多市场一体化平台。单一平台同时支持 DSCSA、欧盟 FMD、印度 CDSCO 与 DGFT iVEDA、俄罗斯 CRPT、阿联酋 Tatmeen、沙特 RSD、巴西 ANVISA、土耳其 ITS 等多国法规；相比多套系统并行部署，可大幅降低复杂度与成本。

4：Build aggregation in from day one. Retrofitting aggregation onto a serialization-only line is significantly more expensive than designing both into the initial scope, and aggregation is now effectively a global default.

从项目初期就纳入包装聚合能力。仅完成序列化的产线后期改造新增聚合功能，成本远高于在初始方案中同步设计序列化与聚合；包装聚合目前事实上已是全球通用标配。

5：Adopt EPCIS 2.0 capability. It is the future of partner exchange and the foundation of cloud-first interoperability. Avoid proprietary data formats that create vendor lock-in.

具备 EPCIS 2.0 能力。EPCIS 2.0 是贸易伙伴数据交互的未来方向，也是云优先互操作性的基础。避免使用会造成供应商锁定的私有数据格式。

6：Invest in trading partner onboarding tools. Every new partner is a potential failure point, and partner onboarding is consistently the slowest activity in any serialization program.

投入建设贸易伙伴接入工具。每一个新增合作方都可能成为风险点；贸易伙伴接入工作，历来是序列化项目中耗时最长的环节。

7：Treat serialization data as a strategic asset. Feed it into recall management, supply chain analytics, AI-driven anomaly detection, anti-diversion intelligence, and partner performance scoring.

将序列化数据作为战略资产。把数据应用于召回管理、供应链分析、AI 异常识别、串货智能监控以及贸易伙伴绩效评估。（译者注：AI→Application Identifier 应用标识符）

8：Plan for combination products holistically. If your portfolio includes prefilled syringes, autoinjectors, inhalers, or other drug-device combinations, integrate UDI labeling and GUDID submission alongside drug-side DSCSA and FMD obligations.

对药械组合产品进行整体规划。若产品管线包含预充针、自动注射器、吸入器等药械组合产品，需在满足药品端 DSCSA、FMD 义务的同时，统筹落实器械 UDI 标签与 GUDID 上报要求。

9：Build a cross-functional governance model. Serialization touches Operations, Quality, IT, Regulatory, Supply Chain, Procurement, and Commercial. Single-function ownership consistently fails.

建立跨职能治理模式。序列化工作涉及生产、质量、IT、法规、供应链、采购、市场等部门。由单一部门全权负责的模式往往会失败。

10：Prepare for the next regulatory layer. EU Digital Product Passports, blockchain-anchored traceability pilots, AI-powered serialization analytics, crypto-enhanced DataMatrix codes, and patient-facing verification apps are all advancing. Companies treating serialization as a living capability rather than a compliance checkbox will lead the next decade.

为下一代监管要求做好准备。欧盟数字产品护照、基于区块链的追溯试点、应用标识符Application Identifier （AI ）序列化数据分析、加密增强型 DataMatrix 码、面向患者的药品核验应用均在持续发展。那些将序列化视为持续演进能力，而非仅仅完成合规打卡的企业，将引领下一个十年。

The Future of Pharma Serialization制药序列化的未来展望

By 2027 and 2028, several trends will reshape the serialization landscape.

到 2027–2028 年，多项趋势将重塑序列化行业格局。

AI-powered serialization analytics will move from pilot to mainstream, with anomaly detection, predictive recall management, partner performance scoring, and supply chain risk analytics becoming standard expectations rather than differentiators.

基于应用标识符Application Identifier（AI）的序列化数据分析将从试点走向大规模落地。异常检测、预测性召回管理、贸易伙伴绩效评分与供应链风险分析会成为行业标配，不再是企业差异化竞争优势。

EPCIS 2.0 will be the default for new implementations, replacing the widely deployed 1.2 version with JSON-based REST APIs better suited to cloud-native networks.

EPCIS 2.0 将成为新项目的默认标准，取代当前广泛使用的 1.2 版本；其基于 JSON 的 REST API 架构更适配云原生网络。

Blockchain-anchored event ledgers, already piloted in Ethiopia and parts of India, will move into mainstream adoption in select markets.

依托区块链的事件账本已在埃塞俄比亚及印度部分地区开展试点，后续将在部分国家进入规模化应用。

Digital Product Passports under the EU Ecodesign for Sustainable Products Regulation will extend serialization into sustainability, ingredient origin, and carbon data, building on existing serialization infrastructure.

欧盟可持续产品生态设计法规下的数字产品护照，将在现有序列化基础设施基础上，把序列化能力延伸至可持续性、原料来源与碳足迹数据管理领域。

Crypto-enhanced DataMatrix codes, currently used in Russia, Kazakhstan, and Uzbekistan, will spread further across the Eurasian Economic Union and possibly into other regulatory regimes.

加密增强型 DataMatrix 码目前已在俄罗斯、哈萨克斯坦、乌兹别克斯坦投入使用，后续将在欧亚经济联盟进一步推广，并有可能进入其他监管辖区。

Direct-to-patient verification apps, where consumers scan packs to confirm authenticity, will start to reach measurable adoption, particularly in India where the QR code framework is explicitly designed for patient verification.

面向患者端的药品核验 APP（消费者扫码核验药品真伪）的普及率将实现显著增长；印度尤为突出，其二维码体系本身就是专为患者核验设计。

Vendor consolidation will continue. Antares Vision’s 2021 acquisition of rfxcel set the template. Expect further M&A as larger players acquire specialized capabilities in AI, authentication, dispenser tools, and emerging market coverage.

供应商行业整合将持续。Antares Vision 在 2021 年收购 rfxcel 奠定了行业并购范式。大型厂商会继续通过并购，获取应用标识符Application Identifier（AI）、防伪核验、调配机构工具以及新兴市场覆盖等专业能力。

For pharmaceutical manufacturers, CDMOs, wholesalers, dispensers, and MAHs, the trajectory is clear. Pharma serialization has moved from compliance obligation to intelligent supply chain infrastructure. The companies treating it as a strategic data and intelligence asset are the ones best positioned to win in the next decade of global pharmaceutical commerce.

对于制药企业、CDMO、批发商、药品调配机构以及上市许可持有人（MAH）而言，发展趋势已经十分清晰：制药序列化已经从一项合规义务，转变为智能化供应链基础设施。那些将序列化视作战略数据与智能资产的企业，最有机会在下一个十年的全球医药市场中占据优势。

Frequently Asked Questions常见问答

Q1. What is pharma serialization and why does it matter?

Pharma serialization is the practice of assigning a unique, machine-readable identifier to every saleable pharmaceutical pack, recording its movement through the supply chain, and exchanging that data with regulators and trading partners. It matters because it protects patients from counterfeit and substandard medicines, satisfies regulatory mandates in 78+ countries, enables granular recalls, defends against diversion, and unlocks supply chain intelligence.

问题1：什么是制药序列化，它为何重要？

制药序列化是为每一个可销售药品包装分配唯一的机器可读标识，记录其在供应链中的流转，并与监管机构、贸易伙伴交换相关数据。其重要性体现在：保护患者免受假药与劣药危害；满足全球 78 个以上国家的法规强制要求；支持精细化召回；防范药品串货；挖掘供应链数据价值。

Q2. What is the difference between serialization, track and trace, and aggregation?

问题 2：序列化、产品追溯、包装聚合三者有什么区别？

Serialization assigns a unique identifier to each pack. Aggregation links packs into parent-child packaging hierarchies (unit, bundle, case, pallet). Track and trace is the broader system that records and exchanges supply chain event data using all three capabilities together. You cannot have meaningful track and trace without serialization, and you cannot have efficient track and trace at scale without aggregation.

序列化是为每个包装分配唯一标识；包装聚合是建立包装之间的父子层级关联（销售单元、捆包、外箱、托盘）；产品追溯是一套范围更广的系统，整合上述能力，记录并交换供应链事件数据。没有序列化，就无法实现有效的产品追溯；没有聚合，则无法规模化高效开展追溯。

Q3. Which countries require pharma serialization in 2026?

问题 3：2026 年，哪些国家强制要求制药序列化？

 As of 2026, more than 78 countries enforce some form of pharma serialization. The major mandates include the United States (DSCSA), the European Union and EEA (FMD), India (CDSCO and DGFT iVEDA), Russia (Chestny ZNAK), China (NMPA), Brazil (ANVISA SNCM), Turkey (ITS), Saudi Arabia (SFDA RSD), the UAE (Tatmeen), South Korea (KPIS), Argentina (ANMAT), and many others, with new mandates rolling out in Egypt, Indonesia, Ethiopia, Nigeria, Jordan, and Lebanon.

截至 2026 年，全球超过 78 个国家实施制药序列化相关强制法规。主要监管体系包括：美国（DSCSA）、欧盟 / 欧洲经济区（FMD）、印度（CDSCO 与 DGFT iVEDA）、俄罗斯（诚实标识 Chestny ZNAK）、中国（NMPA）、巴西（ANVISA SNCM）、土耳其（ITS）、沙特（SFDA RSD）、阿联酋（Tatmeen）、韩国（KPIS）、阿根廷（ANMAT）等。埃及、印尼、埃塞俄比亚、尼日利亚、约旦、黎巴嫩也正在陆续落地新的序列化法规。

Q4. What are the core differences between DSCSA and EU FMD?

问题 4：DSCSA 与欧盟 FMD 的核心差异是什么？

DSCSA uses partner-to-partner EPCIS data exchange with the Verification Router Service for verification, does not legally mandate aggregation but commercially expects it, and applies trading-partner ATP credentialing. EU FMD uses a centralized European Medicines Verification System with point-of-dispense verification at pharmacies and hospitals, leaves aggregation voluntary, and requires a tamper-evident device on every prescription pack in addition to the unique identifier.

DSCSA 采用贸易伙伴之间 EPCIS 点对点数据交换，依靠验证路由服务完成核验；法规层面不强制聚合，但商业层面普遍要求；实施授权贸易伙伴 ATP 资质管理。欧盟 FMD 采用集中式欧洲药品验证系统，在药房、医院等药品调配端完成核验；聚合属于自愿实施；除唯一标识码外，所有处方药包装还必须加装防拆封防伪装置。

Q5. Can one platform handle DSCSA, EU FMD, and other global mandates simultaneously?

问题 5：单个平台能否同时满足 DSCSA、欧盟 FMD 以及其他全球各国法规？

Yes. Modern multi-market serialization platforms (TraceLink Opus, SAP ATTP, Systech UniTrace, OPTEL VerifyBrand, Antares Vision plus rfxcel, Movilitas Cloud, tracekey mytracekey PHARMA, Arvato CSDB, and others) are specifically designed for multi-market compliance from a single codebase. Running parallel single-market systems is dramatically more expensive and operationally complex.

可以。现代化多市场序列化平台（TraceLink Opus、SAP ATTP、Systech UniTrace、OPTEL VerifyBrand、Antares Vision+rfxcel、Movilitas Cloud、tracekey mytracekey PHARMA、Arvato CSDB 等）均基于一套底层代码开发，专门用于满足多国合规。如果并行部署多套仅适配单一国家的系统，成本和运维复杂度会大幅上升。

Q6. What is EPCIS and why is it central to pharma serialization? EPCIS (Electronic Product

问题 6：什么是 EPCIS？为什么它在制药序列化中处于核心地位？

Code Information Services) is the GS1 standard for exchanging supply chain event data. It defines what events occurred, when, where, and why. EPCIS is the de facto language of DSCSA partner data exchange and the global standard for serialization data interoperability. EPCIS 1.2 is the most widely deployed version, with EPCIS 2.0 (JSON-based, REST API-native) emerging as the new standard for cloud-first networks.

EPCIS（电子产品代码信息服务）是 GS1 制定的供应链事件数据交换标准，定义了事件类型、发生时间、地点与原因。EPCIS 是 DSCSA 贸易伙伴数据交换的事实标准，也是序列化数据互操作的全球通用规范。当前 EPCIS 1.2 应用最广泛；基于 JSON、原生支持 REST API 的 EPCIS 2.0，正在成为云优先网络的新标准。

Q7. How does pharma serialization apply to combination products and medical devices?

问题 7：制药序列化如何适用于药械组合产品与医疗器械？

For combination products containing a device constituent (such as an autoinjector, prefilled syringe, inhaler, or on-body injector), two parallel frameworks apply. Drug-side DSCSA or FMD serialization applies to the medicinal product. UDI (Unique Device Identifier) applies to the device constituent, with submission to the FDA’s Global Unique Device Identification Database (GUDID) and equivalent EU EUDAMED database. The FDA’s June 2025 draft guidance clarified that UDI requirements apply to device constituents on top of, not instead of, drug-side obligations.

对于包含器械组件的药械组合产品（如自动注射器、预充式注射器、吸入器、体表注射装置），需要同时遵守两套监管体系：药品部分需要满足 DSCSA 或 FMD 序列化要求；器械组件需执行 UDI（医疗器械唯一标识），数据提交至 FDA 全球医疗器械唯一标识数据库 GUDID 以及欧盟对应的 EUDAMED 数据库。FDA2025 年 6 月草案指南明确：器械组件 UDI 要求，是在药品端合规义务之外额外增加的要求，不能替代药品端义务。

Q8. How long does it take to implement pharma serialization?

问题 8：实施制药序列化项目需要多久？

A single packaging line typically takes 8 to 14 weeks including validation. A full site rollout takes 4 to 9 months. Enterprise rollouts across multiple sites and markets typically take 12 to 24 months, with global tier-one programs sometimes running 3 or more years. The slowest activities are consistently master data cleanup, trading partner onboarding and testing, and validation.

单条包装产线实施（含验证）通常需要 8–14 周；单个工厂完整落地 4–9 个月；跨多工厂、多市场的企业级项目一般 12–24 个月；头部药企的全球化项目有时长达 3 年以上。项目中最耗时的环节永远是：主数据清洗、贸易伙伴接入与联调测试、系统验证。

Q9. How much does a pharma serialization program cost?

问题 9：制药序列化项目的成本大概是多少？

Costs vary dramatically by company profile. A small dispenser may spend a few thousand dollars annually. A mid-market manufacturer typically invests 200,000 to 800,000 USD in initial implementation. A global tier-one manufacturer rolling out across 60 plus packaging lines in multiple countries can invest 10 to 30 million USD in total program cost over 3 to 5 years. Always demand a fully-loaded 5-year total cost of ownership model from every vendor.

成本根据企业规模差异巨大。小型药品调配机构每年仅需数千美元；中型制药企业初始实施投入通常在 20 万–80 万美元；头部跨国药企在多国 60 条以上产线部署，3–5 年总项目成本可达 1000 万–3000 万美元。务必要求所有候选供应商提供完整覆盖全部开销的 5 年总拥有成本 TCO 测算模型。

Q10. What are the most common reasons pharma serialization programs fail?

问题 10：制药序列化项目失败最常见的原因是什么？

The most common failure factors are underestimating master data cleanup effort, treating serialization as an IT project rather than a cross-functional program, choosing on price alone without evaluating EPCIS depth and exception management, skipping trading partner testing, ignoring aggregation in the initial scope, and lacking a clear strategy for handling exceptions, recalls, and saleable returns. The right governance model and the right vendor partner are equally critical.

最常见失败因素：低估主数据清洗工作量；将序列化单纯视为 IT 项目，而非跨部门项目；仅依据价格选型，未评估 EPCIS 能力与异常管理水平；跳过贸易伙伴联调测试；项目初期不纳入聚合设计；缺少异常、召回、可销售退回药品的清晰处置策略。合适的治理架构与供应商伙伴同样至关重要。

Q11. Is patient-facing pack verification part of pharma serialization?

问题 11：面向患者端的包装验真是否属于制药序列化范畴？

Yes, increasingly. India’s Top 300 brands QR code mandate is explicitly designed for smartphone-based patient verification. The EU’s emerging Digital Product Passport framework will extend this concept. Patient apps and brand-led verification microsites are becoming a competitive differentiator alongside compliance, with leading manufacturers using QR code scans for authentication, post-purchase engagement, and pharmacovigilance reporting.

是的，并且应用越来越广泛。印度销量前 300 品种二维码法规，本身就是为患者使用手机扫码验真设计。欧盟正在推进的数字产品护照体系会进一步拓展该理念。患者端 APP、品牌自建的验真微网站，除了满足合规之外，也逐步成为差异化竞争手段。头部企业利用二维码扫码实现真伪核验、购后用户互动以及药物警戒上报。

Q12. What is the future of pharma serialization beyond 2026?

问题 12：2026 年之后，制药序列化的发展方向是什么？

The next wave will include AI-powered serialization analytics moving from pilot to mainstream, full adoption of EPCIS 2.0 for cloud-native interoperability, blockchain-anchored traceability in select markets, EU Digital Product Passport readiness, crypto-enhanced DataMatrix codes spreading beyond the Eurasian Economic Union, direct-to-patient verification apps reaching meaningful adoption, and continued vendor consolidation as larger players acquire specialized capabilities. Companies treating serialization as a strategic data and intelligence asset will be best positioned for the next decade.

下一轮发展趋势包括：应用标识符Application Identifier（AI） 序列化数据分析从试点走向普及；EPCIS 2.0 全面落地，支撑云原生互操作；部分市场启用区块链存证追溯；企业完成欧盟数字产品护照能力准备；加密增强 DataMatrix 码向欧亚经济联盟以外区域拓展；患者端验真 APP 渗透率显著提升；行业持续并购整合，大厂收购各类专业技术能力。把序列化视作战略数据与智能资产的企业，将在未来十年占据优势。

译者注：以下超链接，都是此专题的相关信息介绍，高度浓缩汇总。

Pharma Serialization Solutions
Track and Trace Pharma
DSCSA Compliance Solutions
EU FMD Serialization Requirements
Serialization Software Pharma
Aggregation Systems for Pharma Packaging
Unique Device Identifier (UDI) Pharma
India Pharma Barcoding Requirements
Serialization Vendors Comparison